M
Marco Valgimigli
Researcher at University of Bern
Publications - 772
Citations - 91095
Marco Valgimigli is an academic researcher from University of Bern. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 105, co-authored 696 publications receiving 69184 citations. Previous affiliations of Marco Valgimigli include University of Düsseldorf & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Letters Regarding Article by Patti et al, “Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study”
TL;DR: Patti et al. as discussed by the authors investigated the effect of pretreating patients undergoing percutaneous coronary intervention (PCI) with 600 mg of clopidogrel versus the conventional 300-mg dose.
Journal ArticleDOI
Digital Gangrene Following Transradial Coronary Angiogram.
Andrea Santucci,Marco Valgimigli +1 more
TL;DR: The authors enjoyed reading the case report by Singh et al. reporting on a vascular complication following transradial access (TRA) in a middle-age woman requiring percutaneous coronary intervention after thrombolysis.
Journal ArticleDOI
Comparison of Bivalirudin Versus Heparin(s) During Percutaneous Coronary Interventions in Patients Receiving Prasugrel: A Propensity-Matched Study
Martial Hamon,Laurent Bonello,Steven P. Marso,Sunil V. Rao,Marco Valgimigli,Freek W.A. Verheugt,Anthony H. Gershlick,Yamei Wang,Jayne Prats,Gabriel Steg,Efthymios N. Deliargyris +10 more
TL;DR: Several percutaneous coronary intervention trials have established that the use of bivalirudin (BIV) is associated with improved patient outcomes and substantial hospital cost savings, relative to heparin‐based regimens ± glycoprotein IIb/IIIa inhibitors (GPIs).
Journal ArticleDOI
Bivalirudin in Current Practice: Melius Abundare Quam Deficere?
TL;DR: The optimal antithrombotic therapy for preventing ischemic complications while limiting bleeding risk in patients with acute coronary syndrome who are undergoing primary percutaneous coronary intervention (pPCI) remains an area of great controversy.
Journal ArticleDOI
New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios
Marco Valgimigli,Gianfranco Percoco,Giordano Cicchitelli,Gianluca Campo,Elisa Gardini,Luca Pellegrino,Patrizia Malagutti,Cristina Giretti,Roberto Ferrari +8 more
TL;DR: To project the potential cost-effectiveness of SES-supported multivessel treatment compared with that of coronary artery bypass grafting, a decision- analytical model was developed from a payer's perspective on the basis of data derived from the current Italian health-care system.